EUCTR2011-001550-29-IT进行中（未招募）1 期
Phase II/III randomized, double-blind study of Sandostatin LAR in combination with Axitinib versus Sandostatin LAR in combination with Placebo in patients with progressive advanced G1-G2 (WHO 2010) neuroendocrine tumors of non-pancreatic origin - Randomized, double-blind study of Sandostatin LAR in combination with Axitinib compared with Sandost
GETNE (GRUPO ESPAñOL DE TUMORES NEUROENDOCRINOS)0 个研究点目标入组 253 人开始时间: 2021年1月7日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 253
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. G1-G2 neuroendocrine tumor (WHO 2010) of histologically confirmed non-pancreatic origin, functioning and nonfunctioning
- •2. Metastatic or locally advanced disease not amenable to treatment with curative intent
- •3. Clinical and/or radiological disease progression documented in the 12 months prior to study entry.
- •4. Patients should have at least one measurable lesion as defined by RECIST 1.1 criteria. Patients should not have undergone local or regional ablative procedures (embolization, cryoablation, radiofrequency ablation, or others) in the 6 months prior to entering the study, unless there are other locations of measurable disease or clear radiological progression after carrying out these procedures (in these cases, local and regional ablation procedures shall be permitted if they have been performed at least 1 month prior to enrollment in the study).
- •5. Ki-67 < 20%
- •6. Prior treatment with somatostatin analogues is allowed
- •7. Prior treatment with interferon is allowed
- •8. Prior treatment is allowed with up to 2 antineoplastic systemic treatment lines different from SAs or IFN (systemic treatment is understood as conventional cytotoxic chemotherapy or new drugs for therapeutic targets as mTOR or other, as long as it is not directed against VEGF/VEGFR). Treatment with SAs or IFN does not count as prior lines of antineoplastic treatment.
- •9. Prior treatment with targeted therapy against VEGF or VEGFR is not allowed.
- •10. Adequate organ function as defined by the following criteria:
- •Absolute neutrophil count = 1500 cells/mm3,
- •Platelet count = 75,000 cells/mm3,
- •Hemoglobin = 9.0 g/dL,
- •AST y ALT = 2.5 x upper limit of normal (ULN), except if liver metastases exist, in which case AST and ALT = 5.0 x ULN is allowed,
- •Total bilirubin = 1.5 x ULN,
- •Serum creatinine = 1.5 x ULN or calculated creatinine clearance = 60 mL/min,
- •Proteinuria < 2+ by reactive strip. If the reactive strip is = 2+, a 24-hour urine sample should be collected and the patient may be eligible if urinary protein excretion is < 2 g every 24 hours.
- •11. Men or women aged = 18 years.
- •12. ECOG performance status 0-2
- •13. Life expectancy = 12 weeks
- •14. At least 4 weeks should pass from the end of the previous systemic treatment with resolution of all treatment-related toxicities to grade = 1 according to NCI CTCAE Version 4.0 or to baseline, except for alopecia or properly treated hypothyroidism.
- •15. No prior evidence of uncontrolled hypertension should exist, as documented by 2 baseline blood pressure readings taken at least 1 hour apart. Baseline readings of systolic blood pressure should be = 150 mm Hg and baseline readings of diastolic pressure should be = 90 mm Hg. Patients whose hypertension is being controlled with antihypertensive therapy are eligible.
- •16. Women (or their partners) should be surgically sterilized or postmenopausal, or must agree to use an effective contraceptive method during and for at least 6 months after receiving study treatment. All women of childbearing age should have a negative pregnancy test (serum/urine) within 7 days prior to starting treatment. Men (or their partners) should be surgically sterilized or must agree to use an effective contraceptive method during and for at least 6 months after receiving study treatment. The definition of an effective contraceptive method must comply with local regulations and will be based on the criterion of the principal investigator or a designated associate. Lactating women may not participate in thi
排除标准
- •1. following types of endocrine tumors will not be included: paraganglioma, adrenal endocrine tumor, thyroid, parathyroid, or pituitary.
- •2. Major surgery within previous 4 weeks, or radiation therapy within 2 weeks prior to the start of treatment. Prior palliative radiotherapy for metastatic lesions is permitted if there is at least one measurable lesion that has not been irradiated (i.e., if there are other non-irradiated target lesions).
- •3. Gastrointestinal abnormalities, including:
- •Inability to swallow oral medication;
- •Need for intravenous feeding;
- •Prior surgical procedures that affect absorption, including total gastric resection;
- •Treatment for active peptic ulcer in the last 6 months;
- •Uncontrolled active gastrointestinal bleeding unrelated to cancer, as evidenced by hematemesis, hematochezia or clinically significant melena in the last 3 months without evidence of resolution documented by endoscopy or colonoscopy;
- •Malabsorption syndromes;
- •Current or anticipated need for treatment with drugs that are potent inhibitors of CYP3A4 (grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, telithromycin, clarithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, and delavirdine) unless they can be replaced by another medication with minimal potential for CYP3A4/5 inhibition. The use of low-dose oral steroids (< 5 mg/day prednisone or equivalent) is allowed. Co-administration of steroids may increase plasma concentrations of axitinib.
- •5. Current use or anticipated need for treatment with drugs that are known potent CYP3A4/5 inducers (carbamazepine, dexamethasone, felbamate, phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin, rifampicin, and St. John's wort) unless they can be replaced by another medication with minimal potential for CYP3A4 induction. Co-administration of CYP3A4/5 inducers may decrease plasma concentrations of axitinib.
- •6. Need for anticoagulant therapy with oral vitamin K antagonists. Low doses of anticoagulants to maintain the patency of a central venous access device or to prevent deep vein thrombosis are permitted. Use with therapeutic doses of low molecular weight heparin is allowed.
- •7. Clinically relevant history of bleeding in the last 6 months, including severe hemoptysis or hematuria, unless it has been due to a treated cause (e.g., completely resected bleeding intestinal tumor).
- •8. Active epilepsy or evidence of brain metastases, spinal cord compression, or carcinomatous meningitis.
- •9. Serious uncontrolled illness or active infections that may interfere with the patient’s ability to receive the study treatment.
- •10. Any of the following events in the 12 months prior to administration of the study drug: myocardial infarction, uncontrolled angina, implantation of a coronary or peripheral bypass, symptomatic congestive heart failure, stroke or transient ischemic attack. Deep vein thrombosis or pulmonary embolism in the prior 6 months.
- •11. Ongoing grade 2 cardiac arrhythmias¿ according to NCI CTCAE: atrial fibrillation of any grade or QTc interval > 450 ms for men or > 470 ms for women.
- •12. Patients with human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome-related disease.
- •13. Prior history of cancer except those treated with curative intent for non-melanoma skin cancer in situ, breast or cervical cancer in situ, or those treated for any cancer with curative intent and no evide
研究者
相似试验
进行中（未招募）
1 期
Randomized, double-blind study of Sandostatin LAR in combination withAxitinib compared with Sandostatin LAR in combination with Placebo inpatients with progressive advanced neuroendocrine tumors of nonpancreaticorigiPatients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pancreatic origin (carcinoids)MedDRA version: 20.0Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001550-29-DEGrupo Español de Tumores Neuroendocrinos253
进行中（未招募）
不适用
A Phase II randomized double-blind study of Santostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pancreatic origin (carcinoids)Patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pancreatic origin (carcinoids)MedDRA version: 14.1Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001550-29-ESGrupo Español de Tumores Neuroendocrinos
未知
2 期
A randomized, double-blind, Phase II/III study of JR-013 in the patients with renal anemia receiving hemodialysis treatmentJPRN-jRCT2080220475KISSEI PHARMACEUTICAL CO.,LTD.
撤回
3 期
A phase III randomized, double-blind study of sunitinib (SU011248, sutent) versus placebo in patients with progressive advanced/ metastatic well-differentiated pancreatic islet cell tumorsneuro endocine tumor10014713cancerNL-OMON30440Pfizer10
已完成
3 期
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects (ING114467)HIVHIV110047438NL-OMON38393GlaxoSmithKline10